About this Journal Submit a Manuscript Table of Contents 
Journal of Neurodegenerative Diseases
Volume 2013 (2013), Article ID 319898, 15 pages
http://dx.doi.org/10.1155/2013/319898
Review Article

Oxidative Stress and Its Clinical Applications in Dementia

Peizhong Mao1,2

1The Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, 505 NW 185th Avenue, Beaverton, OR 97006, USA
2The Departments of Physiology and Pharmacology, Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR 97239, USA

Received 5 June 2012; Accepted 16 July 2012

Academic Editor: Peter Crouch

Copyright © 2013 Peizhong Mao. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. S. Knopman, S. T. DeKosky, J. L. Cummings et al., “Practice parameter: diagnosis of dementia (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology,” Neurology, vol. 56, no. 9, pp. 1143–1153, 2001. View at Scopus
  2. B. T. Hyman, C. H. Phelps, T. G. Beach, et al., “National institute on aging-alzheimer's association guidelines for the neuropathologic assessment of Alzheimer's disease,” Alzheimer's & Dementia, vol. 8, no. 1, pp. 1–13, 2012.
  3. N. S. Schoonenboom, F. E. Reesink, N. A. Verwey, et al., “Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort,” Neurology, vol. 78, no. 1, pp. 47–54, 2012.
  4. M. T. Lin and M. F. Beal, “Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases,” Nature, vol. 443, no. 7113, pp. 787–795, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. L. J. Martin, “Mitochondrial and cell death nechanisms in neurodegenerative diseases,” Pharmaceuticals (Basel), vol. 3, no. 4, pp. 839–915, 2010. View at Publisher · View at Google Scholar
  6. P. Mao and P. H. Reddy, “Aging and amyloid beta-induced oxidative DNA damage and mitochondrial dysfunction in Alzheimer's disease: implications for early intervention and therapeutics,” Biochimica et Biophysica Acta, vol. 1812, no. 11, pp. 1359–1370, 2011.
  7. I. G. McKeith, D. J. Burn, C. G. Ballard et al., “Dementia with Lewy bodies,” Seminars in Clinical Neuropsychiatry, vol. 8, no. 1, pp. 46–57, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. K. A. Jellinger, “Formation and development of Lewy pathology: a critical update,” Journal of Neurology, vol. 256, no. 3, supplement, pp. S270–S279, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. E. B. Mukaetova-Ladinska, R. Monteith, and E. K. Perry, “Cerebrospinal fluid biomarkers for Dementia with Lewy bodies,” International Journal of Alzheimer's Disease, vol. 2010, Article ID 536538, 17 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Mao, A. Ardeshiri, R. Jacks, S. Yang, P. D. Hurn, and N. J. Alkayed, “Mitochondrial mechanism of neuroprotection by CART,” European Journal of Neuroscience, vol. 26, no. 3, pp. 624–632, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Mao, C. K. Meshul, P. Thuillier, N. R. Goldberg, and P. H. Reddy, “CART peptide is a potential endogenous antioxidant and preferentially localized in mitochondria,” PLoS ONE, vol. 7, no. 1, article e29343, 2012. View at Publisher · View at Google Scholar
  12. J. E. Selfridge, L. Eb, J. Lu, and R. H. Swerdlow, “Role of mitochondrial homeostasis and dynamics in Alzheimer's disease,” Neurobiology of Disease. In press.
  13. M. A. Lovell and W. R. Markesbery, “Oxidatively modified RNA in mild cognitive impairment,” Neurobiology of Disease, vol. 29, no. 2, pp. 169–175, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Nunomura, G. Perry, G. Aliev et al., “Oxidative damage is the earliest event in Alzheimer disease,” Journal of Neuropathology and Experimental Neurology, vol. 60, no. 8, pp. 759–767, 2001. View at Scopus
  15. D. Praticò, K. Uryu, S. Leight, J. Q. Trojanoswki, and V. M. Y. Lee, “Increased lipid peroxidation precedes amyloid plaque formation in an animal model of alzheimer amyloidosis,” Journal of Neuroscience, vol. 21, no. 12, pp. 4183–4187, 2001. View at Scopus
  16. L. Migliore, I. Fontana, F. Trippi et al., “Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients,” Neurobiology of Aging, vol. 26, no. 5, pp. 567–573, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Sultana, D. Boyd-Kimball, H. F. Poon et al., “Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD,” Neurobiology of Aging, vol. 27, no. 11, pp. 1564–1576, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Bermejo, S. Martín-Aragón, J. Benedí et al., “Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease,” Immunology Letters, vol. 117, no. 2, pp. 198–202, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. L. L. Torres, N. B. Quaglio, G. T. de Souza, et al., “Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 26, no. 1, pp. 59–68, 2011.
  20. M. A. Lovell and W. R. Markesbery, “Oxidative damage in mild cognitive impairment and early Alzheimer's disease,” Journal of Neuroscience Research, vol. 85, no. 14, pp. 3036–3040, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. L. M. Sayre, D. A. Zelasko, P. L. R. Harris, G. Perry, R. G. Salomon, and M. A. Smith, “4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease,” Journal of Neurochemistry, vol. 68, no. 5, pp. 2092–2097, 1997. View at Scopus
  22. R. Sultana, P. Mecocci, F. Mangialasche, R. Cecchetti, M. Baglioni, and D. A. Butterfield, “Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with alzheimer's disease: insights into the role of oxidative stress in alzheimer's disease and initial investigations into a potential biomarker for this dementing disorder,” Journal of Alzheimer's Disease, vol. 24, no. 1, pp. 77–84, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Laurén, D. A. Gimbel, H. B. Nygaard, J. W. Gilbert, and S. M. Strittmatter, “Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers,” Nature, vol. 457, no. 7233, pp. 1128–1132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. D. J. Kyle, E. Schaefer, G. Patton, and A. Beiser, “Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia,” Lipids, vol. 34, no. 6, supplement, p. S245, 1999. View at Scopus
  25. M. Soderberg, C. Edlund, K. Kristensson, and G. Dallner, “Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease,” Lipids, vol. 26, no. 6, pp. 421–425, 1991. View at Scopus
  26. M. R. Prasad, M. A. Lovell, M. Yatin, H. Dhillon, and W. R. Markesbery, “Regional membrane phospholipid alterations in Alzheimer's disease,” Neurochemical Research, vol. 23, no. 1, pp. 81–88, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Nourooz-Zadeh, E. H. C. Liu, B. Yhlen, E. E. Änggård, and B. Halliwell, “F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease,” Journal of Neurochemistry, vol. 72, no. 2, pp. 734–740, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. T. J. Montine, M. D. Neely, J. F. Quinn et al., “Lipid peroxidation in aging brain and Alzheimer's disease,” Free Radical Biology and Medicine, vol. 33, no. 5, pp. 620–626, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Praticò, V. M. Y. Lee, J. Q. Trojanowski, J. Rokach, and G. A. Fitzgerald, “Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo,” The FASEB Journal, vol. 12, no. 15, pp. 1777–1783, 1998. View at Scopus
  30. G. P. Lim, F. Calon, T. Morihara et al., “A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model,” Journal of Neuroscience, vol. 25, no. 12, pp. 3032–3040, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. C. R. Hooijmans, C. E. E. M. Van der Zee, P. J. Dederen et al., “DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice,” Neurobiology of Disease, vol. 33, no. 3, pp. 482–498, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. D. S. Auld, T. J. Kornecook, S. Bastianetto, and R. Quirion, “Alzheimer's disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies,” Progress in Neurobiology, vol. 68, no. 3, pp. 209–245, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Schliebs and T. Arendt, “The significance of the cholinergic system in the brain during aging and in Alzheimer's disease,” Journal of Neural Transmission, vol. 113, no. 11, pp. 1625–1644, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. M. A. Daulatzai, “Early stages of pathogenesis in memory impairment during normal senescence and Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 20, no. 2, pp. 355–367, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Tamagno, M. Guglielmotto, M. Aragno et al., “Oxidative stress activates a positive feedback between the γ- and β-secretase cleavages of the β-amyloid precursor protein,” Journal of Neurochemistry, vol. 104, no. 3, pp. 683–695, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Shen, Y. Chen, H. Liu et al., “Hydrogen peroxide promotes Aβ production through JNK-dependent activation of γ-secretase,” The Journal of Biological Chemistry, vol. 283, no. 25, pp. 17721–17730, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Zetterberg, E. Mortberg, L. Song, et al., “Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid beta levels in humans,” PLoS ONE, vol. 6, no. 12, article e28263, 2011. View at Publisher · View at Google Scholar
  38. D. S. Bredt, P. M. Hwang, C. E. Glatt, C. Lowenstein, R. R. Reed, and S. H. Snyder, “Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase,” Nature, vol. 351, no. 6329, pp. 714–718, 1991. View at Publisher · View at Google Scholar · View at Scopus
  39. D. S. Bredt and S. H. Snyder, “Transient nitric oxide synthase neurons in embryonic cerebral cortical plate, sensory ganglia, and olfactory epithelium,” Neuron, vol. 13, no. 2, pp. 301–313, 1994. View at Publisher · View at Google Scholar · View at Scopus
  40. S. A. Austin, A. V. Santhanam, and Z. S. Katusic, “Endothelial nitric oxide modulates expression and processing of amyloid precursor protein,” Circulation Research, vol. 107, no. 12, pp. 1498–1502, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Arlt, F. Schulze, M. Eichenlaub et al., “Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease,” Dementia and Geriatric Cognitive Disorders, vol. 26, no. 1, pp. 58–64, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. N. V. Morgan, S. K. Westaway, J. E. V. Morton et al., “PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron,” Nature Genetics, vol. 38, no. 7, pp. 752–754, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. E. Grünblatt, J. Bartl, and P. Riederer, “The link between iron, metabolic syndrome, and Alzheimer's disease,” Journal of Neural Transmission, vol. 118, no. 3, pp. 371–379, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Mcneill and P. F. Chinnery, “Neurodegeneration with brain iron accumulation,” Handbook of Clinical Neurology, vol. 100, pp. 161–172, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. M. A. Smith, P. L. R. Harris, L. M. Sayre, and G. Perry, “Iron accumulation in Alzheimer disease is a source of redox-generated free radicals,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 18, pp. 9866–9868, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. M. A. Smith, X. Zhu, M. Tabaton et al., “Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment,” Journal of Alzheimer's Disease, vol. 19, no. 1, pp. 353–372, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. P. K. Mandal, M. Tripathi, and S. Sugunan, “Brain oxidative stress: detection and mapping of anti-oxidant marker “Glutathione” in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy,” Biochemical and Biophysical Research Communications, vol. 417, no. 1, pp. 43–48, 2012.
  48. H. Vural, H. Demirin, Y. Kara, I. Eren, and N. Delibas, “Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease,” Journal of Trace Elements in Medicine and Biology, vol. 24, no. 3, pp. 169–173, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Y. Aksenov, H. M. Tucker, P. Nair et al., “The expression of key oxidative stress-handling genes in different brain regions in Alzheimer's disease,” Journal of Molecular Neuroscience, vol. 11, no. 2, pp. 151–164, 1998. View at Scopus
  50. M. A. Lovell, C. Xie, and W. R. Markesbery, “Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease,” Neurology, vol. 51, no. 6, pp. 1562–1566, 1998. View at Scopus
  51. E. Barone, F. Di Domenico, G. Cenini et al., “Oxidative and nitrosative modifications of biliverdin reductase-A in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment,” Biochimica et Biophysica Acta, vol. 25, no. 4, pp. 623–633, 2011. View at Scopus
  52. E. Barone, C. Mancuso, F. Di Domenico, et al., “Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease,” Journal of Neurochemistry, vol. 120, no. 1, pp. 135–146, 2012.
  53. E. Barone, F. Di Domenico, R. Sultana, et al., “Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment,” Free Radical Biology & Medicine, vol. 52, no. 11-12, pp. 2292–2301, 2012.
  54. R. A. Nixon and A. M. Cataldo, “The endosomal-lysosomal system of neurons: new roles,” Trends in Neurosciences, vol. 18, no. 11, pp. 489–496, 1995. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Smythies, “What is the function of receptor and membrane endocytosis at the postsynaptic neuron?” Proceedings of the Royal Society B, vol. 267, no. 1450, pp. 1363–1367, 2000. View at Scopus
  56. S. Grimm, A. Hoehn, K. J. Davies, and T. Grune, “Protein oxidative modifications in the ageing brain: consequence for the onset of neurodegenerative disease,” Free Radical Research, vol. 45, no. 1, pp. 73–88, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. A. M. Cataldo, D. J. Hamilton, J. L. Barnett, P. A. Paskevich, and R. A. Nixon, “Abnormalities of the endosomal-lysosomal system in Alzheimer's disease: relationship to disease pathogenesis,” Advances in Experimental Medicine and Biology, vol. 389, pp. 271–280, 1996. View at Scopus
  58. A. M. Cataldo, D. J. Hamilton, J. L. Barnett, P. A. Paskevich, and R. A. Nixon, “Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease,” Journal of Neuroscience, vol. 16, no. 1, pp. 186–199, 1996. View at Scopus
  59. A. M. Cataldo, J. L. Barnett, C. Pieroni, and R. A. Nixon, “Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased β-amyloidogenesis,” Journal of Neuroscience, vol. 17, no. 16, pp. 6142–6151, 1997. View at Scopus
  60. T. Grune and K. J. Davies, “Breakdown of oxidized proteins as a part of secondary antioxidant defenses in mammalian cells,” Biofactors, vol. 6, no. 2, pp. 165–172, 1997. View at Scopus
  61. P. Mao, M. Manczak, M. J. Calkins, et al., “Mitochondria-targeted catalase reduces abnormal APP processing, amyloid beta production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension,” Human Molecular Genetics, vol. 21, no. 13, pp. 2973–2990, 2012.
  62. S. E. Schriner, N. J. Linford, G. M. Martin et al., “Medecine: extension of murine life span by overexpression of catalase targeted to mitochondria,” Science, vol. 308, no. 5730, pp. 1909–1911, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. M. J. De Leon, S. Desanti, R. Zinkowski et al., “MRI and CSF studies in the early diagnosis of Alzheimer's disease,” Journal of Internal Medicine, vol. 256, no. 3, pp. 205–223, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Brys, L. Glodzik, L. Mosconi et al., “Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 16, no. 2, pp. 351–362, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Blennow and H. Zetterberg, “Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?” Alzheimer's Research and Therapy, vol. 2, no. 2, article 8, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. G. M. McKhann, D. S. Knopman, H. Chertkow et al., “The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease,” Alzheimer's and Dementia, vol. 7, no. 3, pp. 263–269, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. D. Prvulovic and H. Hampel, “Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease,” Clinical Chemistry and Laboratory Medicine, vol. 49, no. 3, pp. 367–374, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. S. Vos, I. van Rossum, L. Burns, et al., “Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI,” Neurobiology of Aging, vol. 33, no. 10, pp. 2272–2281, 2012.
  69. R. J. Perrin, A. M. Fagan, and D. M. Holtzman, “Multimodal techniques for diagnosis and prognosis of Alzheimer's disease,” Nature, vol. 461, no. 7266, pp. 916–922, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. I. G. McKeith, D. Galasko, K. Kosaka et al., “Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop,” Neurology, vol. 47, no. 5, pp. 1113–1124, 1996. View at Scopus
  71. I. G. McKeith, D. W. Dickson, J. Lowe et al., “Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium,” Neurology, vol. 65, no. 12, pp. 1863–1872, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. J. B. Leverenz, I. Umar, Q. Wang et al., “Proteomic identification of novel proteins in cortical Lewy bodies,” Brain Pathology, vol. 17, no. 2, pp. 139–145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. T. G. Beach, C. H. Adler, L. I. Sue et al., “Reduced striatal tyrosine hydroxylase in incidental Lewy body disease,” Acta Neuropathologica, vol. 115, no. 4, pp. 445–451, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. W. Maetzler, S. P. Schmid, I. Wurster et al., “Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases,” Movement Disorders, vol. 26, no. 1, pp. 176–181, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. L. Warr and Z. Walker, “Identification of biomarkers in Lewy-body disorders,” Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 56, no. 1, pp. 39–54, 2012.
  76. N. Sinha, M. Firbank, and J. T. O'Brien, “Biomarkers in dementia with Lewy bodies: a review,” International Journal of Geriatric Psychiatry, vol. 27, no. 5, pp. 443–453, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. E. Dalfó, M. Portero-Otín, V. Ayala, A. Martínez, R. Pamplona, and I. Ferrer, “Evidence of oxidative stress in the neocortex in incidental Lewy body disease,” Journal of Neuropathology and Experimental Neurology, vol. 64, no. 9, pp. 816–830, 2005. View at Scopus
  78. E. Dalfó and I. Ferrer, “Early α-synuclein lipoxidation in neocortex in Lewy body diseases,” Neurobiology of Aging, vol. 29, no. 3, pp. 408–417, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Navarro, A. Boveris, M. J. Bández et al., “Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies,” Free Radical Biology and Medicine, vol. 46, no. 12, pp. 1574–1580, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. P. Mao, P. Gallagher, S. Nedungadi, et al., “Mitochondrial DNA deletions and differential mitochondrial DNA content in Rhesus monkeys: implications for aging,” Biochimica et Biophysica Acta, vol. 1822, no. 2, pp. 111–119, 2012.
  81. K. Kume, M. Kikukawa, H. Hanyu, et al., “Telomere length shortening in patients with dementia with Lewy bodies,” European Journal of Neurology, vol. 19, no. 6, pp. 905–910, 2012. View at Publisher · View at Google Scholar
  82. A. M. Valdes, T. Andrew, J. P. Gardner et al., “Obesity, cigarette smoking, and telomere length in women,” The Lancet, vol. 366, no. 9486, pp. 662–664, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. J. M. J. Houben, H. J. J. Moonen, F. J. van Schooten, and G. J. Hageman, “Telomere length assessment: biomarker of chronic oxidative stress?” Free Radical Biology and Medicine, vol. 44, no. 3, pp. 235–246, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Balasubramanyam, A. Adaikalakoteswari, Z. Sameermahmood, and V. Mohan, “Biomarkers of oxidative stress: methods and measures of oxidative DNA damage (COMET assay) and telomere shortening,” Methods in Molecular Biology, vol. 610, pp. 245–261, 2010. View at Scopus
  85. S. Masi, K. D. Salpea, K. Li et al., “Oxidative stress, chronic inflammation, and telomere length in patients with periodontitis,” Free Radical Biology and Medicine, vol. 50, no. 6, pp. 730–735, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. O. M. Wolkowitz, S. H. Mellon, E. S. Epel et al., “Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress—preliminary findings,” PLoS ONE, vol. 6, no. 3, article e17837, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. K. D. Salpea, P. J. Talmud, J. A. Cooper et al., “Association of telomere length with type 2 diabetes, oxidative stress and UCP2 gene variation,” Atherosclerosis, vol. 209, no. 1, pp. 42–50, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. A. M. Valdes, I. J. Deary, J. Gardner et al., “Leukocyte telomere length is associated with cognitive performance in healthy women,” Neurobiology of Aging, vol. 31, no. 6, pp. 986–992, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. F. Grodstein, M. van Oijen, M. C. Irizarry et al., “Shorter telomeres may mark early risk of dementia: preliminary analysis of 62 participants from the Nurses' Health Study,” PLoS ONE, vol. 3, no. 2, article e1590, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Ahmad, C. S. Burns, A. L. Fink, and V. N. Uversky, “Peculiarities of copper binding to alpha-synuclein,” Journal Biomolecular Structure and Dynamics, vol. 29, no. 4, pp. 825–842, 2012.
  91. A. Gómez and I. Ferrer, “Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in lewy body diseases,” Journal of Neuroscience Research, vol. 87, no. 4, pp. 1002–1013, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. J. H. T. Power and P. C. Blumbergs, “Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson's disease and dementia with Lewy bodies,” Acta Neuropathologica, vol. 117, no. 1, pp. 63–73, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. M. Manczak, P. Mao, M. J. Calkins et al., “Mitochondria-targeted antioxidants protect against amyloid-β toxicity in Alzheimer's disease neurons,” Journal of Alzheimer's Disease, vol. 20, no. 2, supplement, pp. S609–S631, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg, “Cerebrospinal fluid and plasma biomarkers in Alzheimer disease,” Nature Reviews Neurology, vol. 6, no. 3, pp. 131–144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. N. Andreasen, L. Minthon, A. Clarberg et al., “Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample,” Neurology, vol. 53, no. 7, pp. 1488–1494, 1999. View at Scopus
  96. H. Hampel, S. J. Teipel, T. Fuchsberger et al., “Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment,” Molecular Psychiatry, vol. 9, no. 7, pp. 705–710, 2004. View at Scopus
  97. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon, “Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study,” The Lancet Neurology, vol. 5, no. 3, pp. 228–234, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. A. M. Fagan, C. M. Roe, C. Xiong, M. A. Mintun, J. C. Morris, and D. M. Holtzman, “Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults,” Archives of Neurology, vol. 64, no. 3, pp. 343–349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. P. Lewczuk, J. Kornhuber, H. Vanderstichele et al., “Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study,” Neurobiology of Aging, vol. 29, no. 6, pp. 812–818, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. N. Mattsson, H. Zetterberg, O. Hansson et al., “CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment,” Journal of the American Medical Association, vol. 302, no. 4, pp. 385–393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. L. M. Shaw, H. Vanderstichele, M. Knapik-Czajka et al., “Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI,” Acta Neuropathologica, vol. 121, no. 5, pp. 597–609, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. D. R. Lachno, M. J. Romeo, E. R. Siemers, et al., “Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies,” Journal of Alzheimer's Disease, vol. 26, no. 3, pp. 531–541, 2011.
  103. H. Vanderstichele, M. Bibl, S. Engelborghs, et al., “Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative,” Alzheimer's and Dementia, vol. 8, no. 1, pp. 65–73, 2012.
  104. J. H. Kang, H. Vanderstichele, J. Q. Trojanowski, and L. M. Shaw, “Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease,” Methods, vol. 56, no. 4, pp. 484–493, 2012.
  105. M. Wagner, S. Wolf, F. M. Reischies, et al., “Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease,” Neurology, vol. 78, no. 6, pp. 379–386, 2012.
  106. R. H. Swerdlow and G. A. Jicha, “Alzheimer disease: can the exam predict the pathology?” Neurology, vol. 78, no. 6, pp. 374–375, 2012.
  107. N. Mattsson, H. Zetterberg, O. Hansson et al., “Age and diagnostic performance of Alzheimer disease CSF biomarkers,” Neurology, vol. 78, no. 7, pp. 468–476, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. L. Glodzik-Sobanska, E. Pirraglia, M. Brys et al., “The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease,” Neurobiology of Aging, vol. 30, no. 5, pp. 672–681, 2009. View at Publisher · View at Google Scholar · View at Scopus
  109. C. N. Bassett, M. D. Neely, K. R. Sidell, W. R. Markesbery, L. L. Swift, and T. J. Montine, “Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer's disease and are neurotoxic when oxidized ex vivo,” Lipids, vol. 34, no. 12, pp. 1273–1280, 1999. View at Scopus
  110. T. J. Montine, M. F. Beal, M. E. Cudkowicz et al., “Increased CSF F2-isoprostane concentration in probable AD,” Neurology, vol. 52, no. 3, pp. 562–565, 1999. View at Scopus
  111. K. S. Montine, J. F. Quinn, J. Zhang et al., “Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases,” Chemistry and Physics of Lipids, vol. 128, no. 1-2, pp. 117–124, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. T. J. Montine, J. A. Kaye, K. S. Montine, L. McFarland, J. D. Morrow, and J. F. Quinn, “Cerebrospinal fluid Aβ42, tau, and F2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls,” Archives of Pathology and Laboratory Medicine, vol. 125, no. 4, pp. 510–512, 2001. View at Scopus
  113. T. J. Montine, E. R. Peskind, J. F. Quinn, A. M. Wilson, K. S. Montine, and D. Galasko, “Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers,” Neuromolecular Medicine, vol. 13, no. 1, pp. 37–43, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. J. M. Ringman, S. G. Younkin, D. Pratico et al., “Biochemical markers in persons with preclinical familial Alzheimer disease,” Neurology, vol. 71, no. 2, pp. 85–92, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. L. Mosconi, L. Glodzik, R. Mistur et al., “Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's,” Biological Psychiatry, vol. 68, no. 10, pp. 913–921, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. C. M. Gao, A. Y. Yam, X. Wang et al., “Aβ40 oligomers identified as a potential biomarker for the diagnosis of alzheimer's disease,” PLoS ONE, vol. 5, no. 12, article e15725, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. C. Isobe, T. Abe, and Y. Terayama, “Increase in the oxidized/total coenzyme q-10 ratio in the cerebrospinal fluid of alzheimer's disease patients,” Dementia and Geriatric Cognitive Disorders, vol. 28, no. 5, pp. 449–454, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Bibl, B. Mollenhauer, P. Lewczuk et al., “Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias,” Molecular Psychiatry, vol. 12, no. 7, pp. 671–680, 2007. View at Publisher · View at Google Scholar · View at Scopus
  119. B. Mollenhauer, H. Esselmann, C. Trenkwalder et al., “CSF amyloid-β peptides in neuropathologically diagnosed dementia with lewy bodies and alzheimer's disease,” Journal of Alzheimer's Disease, vol. 24, no. 2, pp. 383–391, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. C. H. Konings, M. A. Kuiper, T. Teerlink, C. Mulder, P. Scheltens, and E. C. Wolters, “Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy,” Journal of the Neurological Sciences, vol. 168, no. 2, pp. 112–115, 1999. View at Publisher · View at Google Scholar · View at Scopus
  121. F. Boström, O. Hansson, L. Gerhardsson et al., “CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies,” Neurobiology of Aging, vol. 30, no. 8, pp. 1265–1271, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. W. Maetzler, V. Stoycheva, B. Schmid et al., “Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in lewy body disease,” Journal of Alzheimer's Disease, vol. 22, no. 3, pp. 933–938, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. W. Maetzler, B. Schmid, M. Synofzik et al., “The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in lewy body disease,” Journal of Alzheimer's Disease, vol. 19, no. 3, pp. 937–942, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. H. M. Nielsen, S. Palmqvist, L. Minthon, E. Londos, and M. Wennström, “Gender-dependent levels of hyaluronic Acid in cerebrospinal fluid of patients with neurodegenerative dementia,” Current Alzheimer Research, vol. 9, no. 3, pp. 257–266, 2012.
  125. G. Rogge, D. Jones, G. W. Hubert, Y. Lin, and M. J. Kuhar, “CART peptides: regulators of body weight, reward and other functions,” Nature Reviews Neuroscience, vol. 9, no. 10, pp. 747–758, 2008. View at Publisher · View at Google Scholar · View at Scopus
  126. M. A. Upadhya, K. T. Nakhate, D. M. Kokare, P. S. Singru, and N. K. Subhedar, “Cocaine- and amphetamine-regulated transcript peptide increases spatial learning and memory in rats,” Life Sciences, vol. 88, no. 7-8, pp. 322–334, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. J. L. Whitwell, S. D. Weigand, M. M. Shiung et al., “Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from alzheimer's disease,” Brain, vol. 130, no. 3, pp. 708–719, 2007. View at Publisher · View at Google Scholar · View at Scopus
  128. Y. S. Piao, K. Wakabayashi, S. Hayashi, M. Yoshimoto, and H. Takahashi, “Aggregation of α-synuclein/NACP in the neuronal and glial cells in diffuse Lewy body disease: a survey of six patients,” Clinical Neuropathology, vol. 19, no. 4, pp. 163–169, 2000. View at Scopus
  129. K. Schultz, S. Wiehager, K. Nilsson et al., “Reduced CSF CART in dementia with Lewy bodies,” Neuroscience Letters, vol. 453, no. 2, pp. 104–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  130. S. Engelborghs, E. Vloeberghs, N. Le Bastard et al., “The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia,” Neurochemistry International, vol. 52, no. 6, pp. 1052–1060, 2008. View at Publisher · View at Google Scholar · View at Scopus
  131. K. R. Shieh, “Effects of the cocaine- and amphetamine-regulated transcript peptide on the turnover of central dopaminergic neurons,” Neuropharmacology, vol. 44, no. 7, pp. 940–948, 2003. View at Publisher · View at Google Scholar · View at Scopus
  132. P. Mao, “Potential antidepressant role of neurotransmitter CART: implications for mental disorders,” Depression Research and Treatment, vol. 2011, Article ID 762139, 11 pages, 2011. View at Publisher · View at Google Scholar
  133. K. Blennow, G. de Meyer, O. Hansson et al., “Evolution of Aβ42 and Aβ40 levels and Aβ42/Aβ40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment,” Journal of Nutrition, Health and Aging, vol. 13, no. 3, pp. 205–208, 2009. View at Publisher · View at Google Scholar · View at Scopus
  134. N. Le Bastard, L. Aerts, J. Leurs, W. Blomme, P. P. De Deyn, and S. Engelborghs, “No correlation between time-linked plasma and CSF Aβ levels,” Neurochemistry International, vol. 55, no. 8, pp. 820–825, 2009. View at Publisher · View at Google Scholar · View at Scopus
  135. E. Mossello, E. Ballini, A. M. Mello et al., “Biomarkers of alzheimer's disease: from central nervous system to periphery?” International Journal of Alzheimer's Disease, vol. 2011, Article ID 342980, 7 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  136. O. Hansson, H. Zetterberg, E. Vanmechelen et al., “Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment,” Neurobiology of Aging, vol. 31, no. 3, pp. 357–367, 2010. View at Publisher · View at Google Scholar · View at Scopus
  137. M. Fei, W. Jianghua, M. Rujuan, Z. Wei, and W. Qian, “The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment,” Journal of the Neurological Sciences, vol. 305, no. 1-2, pp. 92–96, 2011. View at Publisher · View at Google Scholar · View at Scopus
  138. F. Di Domenico, R. Coccia, D. A. Butterfield, and M. Perluigi, “Circulating biomarkers of protein oxidation for Alzheimer disease: expectations within limits,” Biochimica et Biophysica Acta, vol. 1814, no. 12, pp. 1785–1795, 2011.
  139. N. Ertekin-Taner, L. H. Younkin, D. M. Yager et al., “Plasma amyloid beta protein is elevated in late-onset alzheimer disease families,” Neurology, vol. 70, no. 8, pp. 596–606, 2008. View at Publisher · View at Google Scholar · View at Scopus
  140. I. Blasko, G. Kemmler, S. Jungwirth et al., “Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease,” American Journal of Geriatric Psychiatry, vol. 18, no. 11, pp. 973–982, 2010. View at Publisher · View at Google Scholar · View at Scopus
  141. T. J. Montine, L. Shinobu, K. S. Montine, et al., “No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls,” Annals of Neurology, vol. 48, no. 6, p. 950, 2000.
  142. T. J. Montine, J. F. Quinn, K. S. Montine, J. A. Kaye, and J. C. S. Breitner, “Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease,” Journal of Alzheimer's Disease, vol. 8, no. 4, pp. 359–367, 2005. View at Scopus
  143. S. Magaki, R. Raghavan, C. Mueller, K. C. Oberg, H. V. Vinters, and W. M. Kirsch, “Iron, copper, and iron regulatory protein 2 in Alzheimer's disease and related dementias,” Neuroscience Letters, vol. 418, no. 1, pp. 72–76, 2007. View at Publisher · View at Google Scholar · View at Scopus
  144. C. Mueller, M. Schrag, A. Crofton, et al., “Altered serum iron and copper homeostasis predicts cognitive decline in mild cognitive impairment,” Journal of Alzheimer's Disease, vol. 29, no. 2, pp. 341–350, 2012.
  145. O. Zengi, A. Karakas, U. Ergun, M. Senes, L. Inan, and D. Yucel, “Urinary 8-hydroxy-2′-deoxyguanosine level and plasma paraoxonase 1 activity with Alzheimer's disease,” Clinical Chemistry Laboratory Medicine, vol. 50, no. 3, pp. 529–534, 2011.
  146. R. H. Swerdlow, “Brain aging, Alzheimer's disease, and mitochondria,” Biochimica et Biophysica Acta, vol. 1812, no. 12, pp. 1630–1639, 2011.
  147. R. H. Swerdlow, “Alzheimer's disease pathologic cascades: who comes first, what drives what,” Neurotoxicity Research, vol. 22, no. 3, pp. 182–194, 2012.
  148. G. Straten, G. W. Eschweiler, W. Maetzler, C. Laske, and T. Leyhe, “Glial cell-line derived neurotrophic factor (GDNF) concentrations in cerebrospinal fluid and serum of patients with early Alzheimer's disease and normal controls,” Journal of Alzheimer's Disease, vol. 18, no. 2, pp. 331–337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  149. M. M. Reddy, R. Wilson, J. Wilson et al., “Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening,” Cell, vol. 144, no. 1, pp. 132–142, 2011. View at Publisher · View at Google Scholar · View at Scopus